Welcome to our dedicated page for Helius Med Technologies news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Helius Med Technologies stock.
Helius Medical Technologies Inc (NASDAQ: HSDT) is a pioneering neurotechnology company focused on non-invasive therapies for neurological deficits. This page provides investors and healthcare professionals with essential updates on HSDT's progress, including regulatory milestones, clinical trial results, and strategic initiatives.
Discover the latest developments surrounding the Portable Neuromodulation Stimulator (PoNS), partnerships with medical institutions, and financial performance updates. Our curated news collection ensures you stay informed about HSDT's advancements in neuroplasticity-based treatments for conditions like multiple sclerosis and traumatic brain injury.
This resource aggregates official press releases, earnings reports, and market-related announcements. Key coverage areas: FDA regulatory updates, clinical study outcomes, executive leadership changes, and technology licensing agreements. Bookmark this page for streamlined access to material information impacting HSDT's position in the medical device sector.
Helius Medical Technologies (NASDAQ:HSDT) announced the publication of a peer-reviewed study demonstrating that translingual neural stimulation (TLNS) with the PoNS device may facilitate structural brain changes leading to functional recovery in patients with mild-to-moderate traumatic brain injury (TBI). The study showed significant increases in grey matter volume in brain regions associated with balance and movement after treatment. This suggests TLNS combined with physical therapy may enhance recovery. The findings contribute to the growing body of evidence supporting the therapeutic potential of PoNS technology.
Helius Medical Technologies (HSDT) announced a peer-reviewed study published in EMJ Radiology highlighting the effectiveness of its Portable Neuromodulation Stimulator (PoNS) in treating balance issues after mild-to-moderate traumatic brain injury (TBI). The study evaluated 9 patients and demonstrated significant increases in grey matter volume within the cerebellum and temporal regions, correlating with improved functional assessments. The research indicates that TLNS combined with physical therapy may effectively address balance disorders.
Helius Medical Technologies (Nasdaq: HSDT) has announced its participation in upcoming investor conferences in September. Key presentations include the LD 500 Virtual Investor Conference on September 1 at 1:20 p.m. ET, the Wall Street Investor Forum Virtual Conference on September 10 at 9:20 a.m. ET, and the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, with its presentation on September 16 at 12:00 p.m. ET. Webcasts will be available on their investor relations website.
Helius Medical Technologies (NASDAQ:HSDT) announced that Philippe Deschamps has resigned as President and CEO, effective August 23, 2020. Dane C. Andreeff and Blane Walter have been appointed as Interim President and CEO, and Chairman, respectively. The Board expressed gratitude for Deschamps' leadership during his seven-year tenure, highlighting the company's transition to a public entity. Andreeff, a board member since 2017, is recognized for his extensive experience in healthcare and is expected to drive Helius' regulatory and operational progress. The PoNS device is currently awaiting FDA clearance.
Helius Medical Technologies (HSDT) reported Q2 2020 financial results, with revenue of $0.1 million, down from $0.5 million in Q2 2019. The operating loss narrowed to $3.7 million from $5.8 million. Net loss was $3.4 million, compared to a $0.2 million loss a year prior. Cash on hand was $5.3 million as of June 30, 2020. Recent developments include receiving Breakthrough Designation for the PoNS™ device and the submission for FDA review. The company anticipates ongoing challenges due to COVID-19 affecting clinic operations in Canada.
Helius Medical Technologies (NASDAQ: HSDT) will announce its second quarter fiscal year 2020 financial results on August 12th, after market close. A conference call, scheduled for the same day at 5:00 p.m. ET, will provide insights into the quarterly performance. Participants can join via phone or through a live webcast available on the investor relations website. The company focuses on neurological wellness, with its first product, the Portable Neuromodulation Stimulator (PoNS), aimed at treating gait deficits from mild to moderate neurological conditions. PoNS is currently under FDA review.
Helius Medical Technologies (NASDAQ: HSDT) has submitted a request to the FDA for de novo classification and clearance of its Portable Neuromodulation Stimulator (PoNS) device, aimed at treating gait deficits in Multiple Sclerosis patients. The device was granted Breakthrough Designation on May 7, 2020. Preliminary Q2 2020 revenue is expected to be $0.1 million, down from $0.5 million in Q2 2019, while operating loss is projected at $3.7 million, an improvement from $5.8 million year-over-year. Cash reserves stand at $5.3 million as of June 30, 2020.
Helius Medical Technologies (Nasdaq: HSDT) announced its participation in the Virtual Summer Summit, scheduled from June 9th-12th, 2020. Management will present on June 9th at 4:30 p.m. ET. A live audio webcast will be available on the company's investor relations website, with an archived replay after the conference.
Helius focuses on neurological wellness, developing non-invasive technologies. Its first product, the Portable Neuromodulation Stimulator (PoNS™), targets gait deficits from neurological conditions.
Helius Medical Technologies (NASDAQ: HSDT) announced Breakthrough Designation for its PoNS™ device, aimed at treating gait deficits in Multiple Sclerosis patients. This designation allows expedited development and assessment by the FDA, with the goal of improving patient mobility through a non-drug treatment approach. The PoNS device is currently authorized in Canada and under investigation in the U.S. and other regions. The Breakthrough Devices Program facilitates timely access for critical medical devices while ensuring compliance with regulatory standards.
Helius Medical Technologies (HSDT) reported Q1 2020 financial results revealing a revenue decline to $0.2 million from $0.7 million in Q1 2019, driven primarily by decreased product sales of $191 thousand. The company experienced an operating loss of $4.0 million, a 41% improvement from the previous year. Net loss was $4.8 million, compared to a net income of $1.3 million in Q1 2019. Cash reserves decreased to $4.4 million as of March 31, 2020. Due to uncertainties from the COVID-19 pandemic, the full-year outlook has been withdrawn.
